Biomarker-directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2013 Jan 30

PMID 23358976

Citations 14

Authors

Floyd Christopher Holsinger

Sarina Anne Piha-Paul

Filip Janku

David S Hong

Johnique T Atkins

Apostolia M Tsimberidou

Razelle Kurzrock

Affiliations

Soon will be listed here.

Citing Articles

The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.

Stefano S, Giovanni S Cancers (Basel). 2019; 11(8).

PMID: 31416195 PMC: 6721622. DOI: 10.3390/cancers11081169.

Biomarker driven treatment of head and neck squamous cell cancer.

Eze N, Lo Y, Burtness B Cancers Head Neck. 2019; 2:6.

PMID: 31093353 PMC: 6460531. DOI: 10.1186/s41199-017-0025-1.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Rodon J, Soria J, Berger R, Miller W, Rubin E, Kugel A Nat Med. 2019; 25(5):751-758.

PMID: 31011205 PMC: 6599610. DOI: 10.1038/s41591-019-0424-4.

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Goodman A, Kato S, Chattopadhyay R, Okamura R, Saunders I, Montesion M Cancer Immunol Res. 2019; 7(6):866-873.

PMID: 31003990 PMC: 6548620. DOI: 10.1158/2326-6066.CIR-18-0716.

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?.

von der Grun J, Rodel F, Brandts C, Fokas E, Guckenberger M, Rodel C Cancers (Basel). 2019; 11(4).

PMID: 30987257 PMC: 6521064. DOI: 10.3390/cancers11040472.

References

Piha-Paul S, Cohen P, Kurzrock R . Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011; 29(26):e727-30. DOI: 10.1200/JCO.2011.36.2095. View

Brizel D, Albers M, Fisher S, Scher R, Richtsmeier W, Hars V . Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338(25):1798-804. DOI: 10.1056/NEJM199806183382503. View

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

Molinolo A, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A . Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res. 2007; 13(17):4964-73. DOI: 10.1158/1078-0432.CCR-07-1041. View

Posner M, Hershock D, Blajman C, Mickiewicz E, Winquist E, Gorbounova V . Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17):1705-15. DOI: 10.1056/NEJMoa070956. View

Shin D, Khuri F . Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2011; 35(3):443-53. DOI: 10.1002/hed.21910. View

Forastiere A, Goepfert H, Maor M, Pajak T, Weber R, Morrison W . Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-8. DOI: 10.1056/NEJMoa031317. View

Gillison M, Koch W, Capone R, Spafford M, Westra W, Wu L . Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92(9):709-20. DOI: 10.1093/jnci/92.9.709. View

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

10.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

11.

Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G . Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006; 66(11):5549-54. DOI: 10.1158/0008-5472.CAN-05-2825. View

12.

Wu X, Senechal K, Neshat M, Whang Y, Sawyers C . The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998; 95(26):15587-91. PMC: 28087. DOI: 10.1073/pnas.95.26.15587. View

13.

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

14.

Magnuson B, Ekim B, Fingar D . Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2011; 441(1):1-21. DOI: 10.1042/BJ20110892. View

15.

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

16.

Janku F, Wheler J, Westin S, Moulder S, Naing A, Tsimberidou A . PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8):777-82. PMC: 3295566. DOI: 10.1200/JCO.2011.36.1196. View

17.

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

18.

Janku F, Tsimberidou A, Garrido-Laguna I, Wang X, Luthra R, Hong D . PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011; 10(3):558-65. PMC: 3072168. DOI: 10.1158/1535-7163.MCT-10-0994. View

19.

Langer C . Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008; 112(12):2635-45. DOI: 10.1002/cncr.23521. View

20.

Hsieh A, Costa M, Zollo O, Davis C, Feldman M, Testa J . Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010; 17(3):249-61. PMC: 2901095. DOI: 10.1016/j.ccr.2010.01.021. View